MAY 1, 2020
Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, Marburg, MERS and SARS. Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19.
The Union Health Ministry on 1st May said that none of the international studies on Covid-19 have produced any conclusive results yet. On being asked about US study on remdesivir, Health Ministry’s Joint Secretary Lav Aggarwal said that the researches conducting the study have said that the trial is still on with some positive outcome, “but again, this is still inconclusive.”
Lav Aggarwal cautioned against hoping too much too soon from studies underway as he said that studies take time and have to go through various stages.
Earlier, the Centre had cautioned the public against seeking the convalescent plasma therapy as the cure Covid-19. While the therapy is being administered at various Covid-19 hospitals across India on a trial basis, Lav Aggarwal had said that it is still an experimental drug.